Browsing Tag
Levi Garraway
8 posts
Roche’s vamikibart sustains vision gains for 52 weeks as July 2027 FDA decision approaches
Genentech has reported sustained visual improvements and reduced retinal swelling through one year in two Phase III studies of vamikibart for uveitic macular edema. Approximately two-thirds of eligible patients required no retreatment after week 16, strengthening the potential treatment's durability profile. However, mixed statistical results between the pivotal trials and the absence of a direct steroid comparison remain important considerations ahead of the expected July 2027 FDA decision.
FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment
The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that…
Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the…
Roche’s Vabysmo gains FDA approval for treating retinal vein occlusion
Pharma giant Roche has secured the U.S. FDA’s approval for Vabysmo (faricimab) in treating macular edema after retinal…
Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody
Switzerland-based Roche has officially declared its acquisition agreement for Telavant Holdings, Inc., a Roivant company collaboratively owned by…
Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial
Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their…
Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC
Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib),…
Genentech gets Actemra FDA approval for COVID-19 in hospitalized adults
Actemra FDA approval : Genentech, a subsidiary of Roche, has received the approval of the US Food and…